Kailera Therapeutics, Inc.
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Ronald C. Renaud Jr.
- Full Time Employees
- 145
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 180 Third Avenue, 4th Floor Waltham MA United States of America 02451
- IPO Date
- Apr 17, 2026
- CIK
- 0002096997
- Website
- kailera.com
- Similar Companies
- Business
- Kailera Therapeutics, Inc. is an American advanced clinical-stage biopharmaceutical company focused on obesity and related metabolic conditions. It develops a diversified portfolio of next-generation GLP-1-based therapies delivered via injectable and oral formats, with lead candidates advancing through global Phase 3 programs and a broader pipeline spanning additional GLP-1 receptor agonists and tri-agonist modalities. Kailera operates primarily in the United States with clinical development activities and collaborations extending to international sites, aiming to provide weight-management options across varied treatment journeys. The company is headquartered in Boston, Massachusetts, and was founded in 2024 to accelerate innovative obesity care solutions. Kailera’s core products and services comprise clinical-stage injectable and oral therapeutics targeting obesity, chronic weight management, and related metabolic comorbidities, including both peptide-based dual-agonist and tri-agonist mechanisms, as well as formulation development for sustained-release or daily-dose regimens; ongoing negotiations and partnerships with major life-sciences investors support its financing and collaboration strategy, while ongoing trials and potential future regulatory filings shape its growth trajectory. Kailera maintains an operating model that emphasizes clinical development, strategic alliances, and a pipeline-driven approach to bring next-generation obesity therapies to patients worldwide.
2 Beaten-Down GLP-1 Stocks to Buy on the Dip
Kailera Therapeutics: A Second-Wave Obesity Platform With More Than One Way To Win
Why Is Kailera Therapeutics Stock Falling Tuesday?
Kailera's GLP-1 drug meets main goal of late-stage trials
Kailera Therapeutics Appoints Kathleen Tregoning as Chief Corporate Affairs Officer
Biotech ETF Index Surges 10% After Rebalance
3 Under-the-Radar Stocks to Buy and Hold for a Decade
Hengrui Pharma and Kailera Therapeutics Present Ribupatide Clinical Data at ADA 2026
Kailera Therapeutics to Present at the 2026 Jefferies Global Healthcare Conference
Kailera Reports First Quarter 2026 Financial Results and Provides Clinical Data Updates
Is Kailera Therapeutics a Buy After Its Sizzling IPO?
This Weight-Loss Drug Challenger Could Follow Eli Lilly's Playbook: Analyst
Hengrui Pharma and Kailera Therapeutics Announce Clinical Data Presentations at the American Diabetes Association 86th Scientific Sessions
A Kailera Therapeutics (KLRA) Insider Scooped up an Additional 500,000 Shares for $8.0 Million
First Look: Meta cuts, Intel beats, oil jumps, Apple shift
Rtw Investments, Lp Acquires 500,000 Shares of Kailera Therapeutics (NASDAQ:KLRA) Stock
Kailera Therapeutics' Strong IPO Validates "NewCo" Strategy
First Look: Tesla beats, WBD vote, oil near $100, AI moves
Kailera Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares
Kailera Therapeutics Debut Marks Largest Biotech IPO Since 2021 Amid Weight Loss Race